help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by RUTGERS, S. R.
Right arrow Articles by POSTMA, D. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by RUTGERS, S. R.
Right arrow Articles by POSTMA, D. S.

Am. J. Respir. Crit. Care Med., Volume 157, Number 3, March 1998, 880-886

Short-term Treatment with Budesonide Does Not Improve Hyperresponsiveness to Adenosine 5'-Monophosphate in COPD

STEVEN R. RUTGERS, GERARD H. KOËTER, THOMAS W. van der MARK, and DIRKJE S. POSTMA

Department of Pulmonology, University Hospital Groningen, Groningen, The Netherlands

The role of inhaled corticosteroids in the treatment of chronic obstructive pulmonary disease (COPD) is unclear. We investigated the effects of budesonide on airway hyperresponsiveness (AHR) to methacholine (MCh) and adenosine 5'-monophosphate (AMP), to which we hypothesized the existence of greater sensitivity. Additionally, we studied the effects of budesonide on terfenadine and ipratropium bromide and on serum levels of interleukin-8 (IL-8) and histamine. Forty-four hyperresponsive smokers with moderate to severe COPD participated in the study. MCh and AMP challenges were given on three study days, after pretreatment with single doses of ipratropium bromide, terfenadine, or placebo. Thereafter, subjects were randomized to 6 wk treatment with either 1,600 µg budesonide or placebo, and the same three study days were repeated. Budesonide, as compared with placebo, did not significantly change PC20AMP, PC20MCh, or FEV1 after placebo pretreatment. Budesonide increased PC20MCh after ipratropium bromide pretreatment, from 5.05 to 10.20 mg/ml (p = 0.036). Budesonide decreased serum IL-8 from 9.2 ± 3.7 to 6.2 ± 2.1 pg/ml (p < 0.001). We conclude that AMP did not elicit greater sensitivity than MCh in assessing short-term effects of budesonide on AHR in smokers with COPD. We suggest that long-term treatment with inhaled corticosteroids might be beneficial, by reducing neutrophil load in the airways and improving the action of anticholinergic drugs.




This article has been cited by other articles:


Home page
 Eur Respir JHome page
L. Huiart, P. Ernst, X. Ranouil, and S. Suissa
Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD
Eur. Respir. J., April 1, 2005; 25(4): 634 - 639.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
B. P. Ponsioen, W. C. J. Hop, N. A. Vermue, P. N. R. Dekhuijzen, and A. M. Bohnen
Efficacy of fluticasone on cough: a randomised controlled trial
Eur. Respir. J., January 1, 2005; 25(1): 147 - 152.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
J. F. Donohue and J. A. Ohar
Effects of Corticosteroids on Lung Function in Asthma and Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, November 1, 2004; 1(3): 152 - 160.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
D. C. Grootendorst and K. F. Rabe
Mechanisms of Bronchial Hyperreactivity in Asthma and Chronic Obstructive Pulmonary Disease
Proceedings of the ATS, April 1, 2004; 1(2): 77 - 87.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
R Polosa, S Rorke, and S T Holgate
Evolving concepts on the value of adenosine hyperresponsiveness in asthma and chronic obstructive pulmonary disease
Thorax, July 1, 2002; 57(7): 649 - 654.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
R. Polosa, M. van den Berge, H. A. M. Kerstjens, and D. S. Postma
ADENOSINE MONOPHOSPHATE CHALLENGE AND MONITORING OF AIRWAY RESPONSE TO ANTIINFLAMMATORY THERAPY
Am. J. Respir. Crit. Care Med., May 1, 2002; 165(9): 1336 - 1336.
[Full Text] [PDF]

Home page
 ThoraxHome page
J Vestbo and E F Hansen
Airway hyperresponsiveness and COPD mortality
Thorax, September 1, 2001; 56(90002): ii11 - 14.
[Full Text] [PDF]

Home page
 ChestHome page
P. G. Gibson, J. L. Simpson, and N. Saltos
Heterogeneity of Airway Inflammation in Persistent Asthma : Evidence of Neutrophilic Inflammation and Increased Sputum Interleukin-8
Chest, May 1, 2001; 119(5): 1329 - 1336.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
The Lung Health Study Research Group
Effect of Inhaled Triamcinolone on the Decline in Pulmonary Function in Chronic Obstructive Pulmonary Disease
N. Engl. J. Med., December 28, 2000; 343(26): 1902 - 1909.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. S. POSTMA and H. A. M. KERSTJENS
Are Inhaled Glucocorticosteroids Effective in Chronic Obstructive Pulmonary Disease?
Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): S66 - 71.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. S. POSTMA and H. A. M. KERSTJENS
Characteristics of Airway Hyperresponsiveness in Asthma and Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med., November 1, 1998; 158(2007): S187 - S192.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1998 American Thoracic Society 		  SOTA, FL